Application of Dydrogesterone and Medroxyprogesterone in Patients after Hysteroscopic Electrocision for Early Endometrial Cancer
Objective:To investigate and compare the application effect of Dydrogesterone and Medroxyprogesterone in patients after hysteroscopic electrocision for early endometrial cancer and influence on tumor markers and sex hormones.Method:A total of 80 patients with early endometrial cancer who were scheduled to undergo hysteroscopic electrocision in Quanzhou Southeast Hospital from January 2020 to June 2021 were divided into group A(40 cases)and group B(40 cases)according to the random number table method.The group A was treated with Dydrogesterone,and the group B was treated with Medroxyprogesterone.Then the total effective rates of treatment,the incidence of adverse reaction,recurrence rates at different time after the operation,tumor markers[serum carbohydrate antigen 125(CA125),carbohydrate antigen19-9(CA19-9)and human epididymis protein 4(HE4)]and sex hormones[serum estradiol(E2),progesterone(P)and luteinizing hormone/follicle stimulating hormone(LH/FSH)]of two groups were compared.Result:The total effective rate of treatment in group B was significantly higher than that in group A,the difference was statistically significant(P<0.05).The incidences of adverse reaction in two groups were compared,the differences were not statistically significant(P>0.05).The recurrence rates of group B at the sixth and twelfth and twenty-fourth month after the operation were significantly lower than those of group A,the differences were statistically significant(P<0.05).Before the operation,the tumor markers and sex hormones of two groups were compared,the differences were not statistically significant(P>0.05);at the third and sixth month after the operation,the tumor markers and E2,LH/FSH of group B were significantly lower than those of group A,the P were significantly higher than those of group A,the differences were statistically significant(P<0.05).Conclusion:The application effect of Medroxyprogesterone in patients with hysteroscopic electrocision for early endometrial cancer is better than those of Dydrogesterone,and it can significantly improve the tumor markers and sex hormones of patients,so the application value of Medroxyprogesterone in patients with hysteroscopic electrocision for early endometrial cancer is relatively higher.
国家科技期刊平台
NSTL
万方数据
